Buying The Most Time: CareDx’s Diagnostics For Transplant Recipients
An organ transplant is not a “one and done” procedure, and patients require lifelong post-operative monitoring. Medtech Insight spoke to CareDx about how monitoring could improve patient outcomes.
You may also be interested in...
Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
AstraZeneca And Huma On Digital’s Value For Pharma
Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.
Podcast: OxSonics Hopes To Use Ultrasound To Enhance Drug Efficacy – Without Reformulation
In this one-off podcast, reporter Barnaby Pickering speaks Jérôme Marzinski and Dr Christian Coviello, the CEO and CTO, respectively, of OxSonics, a UK-based start-up which is working on an ultrasound-based technology that has been designed to enhance the potency of oncological drugs.